(412 days)
The Angiomat Illumena is designed to inject a radiopaque contrast medium into the vascular system for Angiographic or CT procedures as prescribed by qualified health care professionals.
The Angiomat Illumena is designed to inject a radiopaque contrast medium into the vascular system for Angiographic or CT procedures as prescribed by qualified health care professionals. The system is designed to be configured as cither an Angiographic injector or as a CT injector.
The system includes a microprocessor controlled DC servo motor which drives a lead serve ram against the piston of a single use syringe. The operation of the servo is programmed by the operator using a touch screen on an electroluments on display. The system is powered by AC line voltage at 100 Volts, 130 Volts, or 240 Volts. System power is less than 1500 Walls.
A typical Angiomat Illumena system includes a power pack, console, powerhead, syringe holder assembly, ac power cable assembly, start cable assembly, and console cable assembly. Other options include ECCG trigger systems, syringe heater, air detection and warning system, pedestal mounting system. wall/rack/ceiling mounting systems, interface cabling, powerhead and console extension cabling. Start switch variations, and printer system.
The system is designed to deliver contrast from either a prefilled syringe or an unfilled wringe which is filled at the start of the procedure. A reusable, sterilizable syringe is also available.
The system will interface with an X-ray system allowing either the start of injection initiated by the X-ray system or start of X-ray initiated by the injector.
Here's an analysis of the provided text regarding the acceptance criteria and study for the Angiomat Illumena Injector:
Note: The provided document is a 510(k) summary for a medical device. This type of document focuses on demonstrating substantial equivalence to predicate devices rather than deeply detailed, statistically rigorous clinical trials common for novel devices or software. As such, some of the requested information (like specific sample sizes for test sets, the number of experts for ground truth, or MRMC studies) is not typically included in this type of submission and is therefore not present in the provided text.
1. Table of Acceptance Criteria and Reported Device Performance
The acceptance criteria are implicitly defined by the device's ability to perform "to specification within ranges equivalent to the predicate devices with accuracy and precision superior to the predicate devices." The performance reported is that the device meets these specifications.
| Characteristic/Feature | Acceptance Criteria (Implicit from Predicates & Superiority Claim) | Reported Device Performance |
|---|---|---|
| Major Functional Parameters | Performance to specification within ranges equivalent to predicate devices with superior accuracy and precision. | Meets product specifications for the Angiomat Illumena. |
| Programmed flow rate | Equivalent to or superior to predicate devices (0.01 to 40 ml/sec for 125/150 ml syringe) | Meets product specifications. Accuracy validated. |
| Programmed volume | Equivalent to or superior to predicate devices | Meets product specifications. Accuracy validated. |
| Injection duration | Equivalent to or superior to predicate devices | Meets product specifications. |
| Pressure limit | Equivalent to or superior to predicate devices (75 to 1200 PSI) | Meets product specifications. Accuracy validated. |
| Injection/X-ray delay | Equivalent to or superior to predicate devices (e.g., 0-300 sec for both) | Meets product specifications. |
| Operational Robustness | Operation to specification for all conditions of operation, including extremes. | Tests demonstrate operation to specification for all conditions of operation. |
| Fluid Delivery Accuracy | Accurate delivery of programmed volume. | Validated. Delivered volume measured via calibrated equipment, compared to programmed and displayed volumes. |
| Pressure Limit Accuracy | Accurate achievement and display of programmed pressure limit. | Validated. Back pressure accurately measured via calibrated equipment, compared to programmed and displayed values. |
| Flow Rate Delivery Accuracy | Correct algorithm for flow rate, accurate timing, correct drive system incrementation, and accurate achieved flow rate. | Validated. (Four-step process: algorithm verification, servo electronics timing, volume validation, achieved flow rate comparison to spec). |
2. Sample Size Used for the Test Set and the Data Provenance
- Sample Size: Not explicitly stated in terms of number of injections or individual tests. The document refers to "a comprehensive set of tests" and "tests were performed using extremes of operating parameters."
- Data Provenance: The tests directly involve the physical device (Angiomat Illumena Injector) delivering water. This implies the data is prospective as it's generated during the testing phase of the new device. The country of origin for the testing is not specified, but given the company's address and the FDA 510(k) submission, it would likely be in the United States.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and the Qualifications of Those Experts
- Number of Experts: Not applicable. The "ground truth" for these performance tests is based on direct physical measurements using calibrated equipment (e.g., for volume, pressure, time) and comparison against the device's own specifications and programmed parameters. There are no human "experts" establishing a subjective ground truth for these engineering performance metrics.
- Qualifications of Experts: N/A.
4. Adjudication Method for the Test Set
- Adjudication Method: Not applicable. The "adjudication" is based on objective measurements from calibrated equipment compared against predefined specifications. These are not subjective assessments requiring multiple reviewers.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
- MRMC Study: No, an MRMC comparative effectiveness study was not done. This device is an injector, not an imaging analysis or diagnostic AI tool. Its performance is measured by its mechanical and electronic accuracy in delivering contrast medium, not its impact on human reader interpretation of medical images.
6. If a Standalone (i.e. algorithm only without human-in-the-loop performance) was done
- Standalone Performance: Yes, the described performance tests essentially are standalone performance tests. The device's ability to accurately deliver programmed flow, volume, and pressure is evaluated directly, without a human operator's influence on the measured output (beyond programming the device). The tests verify the device's inherent mechanical and electronic accuracy.
7. The Type of Ground Truth Used
- Type of Ground Truth: The ground truth used for these performance tests is objective physical measurement derived from calibrated reference equipment. For example:
- For volume accuracy: Measured delivered volume using calibrated equipment.
- For pressure accuracy: Measured back pressure using calibrated equipment.
- For flow rate accuracy: Verification of algorithms, timing with measurement equipment, and measured delivered volume over time using calibrated equipment.
8. The Sample Size for the Training Set
- Sample Size for Training Set: Not applicable. This device is a hardware injector with embedded software for control, not a machine learning or AI algorithm that "trains" on data in the conventional sense. The "training" for such a system would involve engineering design, calibration, and iterative development rather than a dataset of clinical cases with established ground truth.
9. How the Ground Truth for the Training Set Was Established
- Ground Truth for Training Set: Not applicable. As mentioned above, this is not an AI/ML device that uses a "training set" with ground truth in the typical sense. The "ground truth" for its development would be based on engineering specifications, physical laws, and performance requirements derived from its intended use and predicate devices.
{0}------------------------------------------------
SEP 2 3 1991
K963071
Liebel Flarsheim Company
2111 East Galbraith Road Cincinnati, OH 45215-6305 Phone 800 347 9730 Fax 513 761 2388
Angiomat Illumena Injector 510(k) Summary
September 19, 1997
| Official Contact: | Bridget DrakeCompliance AdministratorLiebel Flarsheim Company2111 East Galbraith RoadCincinnati, OH 45215-6305Phone 513 948 5719Fax 513 761 2388 |
|---|---|
| Classification Name: | Cardiovascular Diagnostic Deviceper CFR 870.1650 |
| Common/Usual Name: | Injector System |
| Proprietary Name: | Angiomat Illumena |
| Predicate Devices: | Angiomat 6000 (K860204)CT 8000/9000 Injector (K912944) |
Device Description:
The Angiomat Illumena is designed to inject a radiopaque contrast medium into the vascular system for Angiographic or CT procedures as prescribed by qualified health care professionals. The system is designed to be configured as cither an Angiographic injector or as a CT injector.
The system includes a microprocessor controlled DC servo motor which drives a lead serve ram against the piston of a single use syringe. The operation of the servo is programmed by the operator using a touch screen on an electroluments on display. The system is powered by AC line voltage at 100 Volts, 130 Volts, or 240 Volts. System power is less than 1500 Walls.
A typical Angiomat Illumena system includes a power pack, console, powerhead, syringe holder assembly, ac power cable assembly, start cable assembly, and console cable assembly. Other options include ECCG trigger systems, syringe heater, air detection and warning system, pedestal mounting system. wall/rack/ceiling mounting systems, interface cabling, powerhead and console extension cabling. Start switch variations, and printer system.
The system is designed to deliver contrast from either a prefilled syringe or an unfilled wringe which is filled at the start of the procedure. A reusable, sterilizable syringe is also available.
The system will interface with an X-ray system allowing either the start of injection initiated by the X-ray system or start of X-ray initiated by the injector.
{1}------------------------------------------------
Major Component Descriptions:
Power Pack (Control Module) - The power pack is the center of the injection system. It communicates with the console (s) and powerhead to receive the user inputs then provides appropriate motor power/control to the powerhead and monitors injection performance in real time. It houses the main circuit breaker, DC power supply, main control PC board, communications PC board, and the servo system. It may also accept plug in options such as the simulated display ECG. All cabling terminates at the power pack.
Console - The console displays graphic and text prompts to the user and reads user responses via a touch screen while communicating with the power pack. It also incorporates a system remote On/Off switch. Within the console are the display, touchscreen, and console CPU PC board. It may also accept the optional dynamic display ECG PC board. The injection system may use either 1 or 2 consoles.
Powerhead - The powerhead actuates the 150ml or 125ml syringes with the assistance of the appropriate syringe holder assembly while communicating with the power pack. It allows both electronic and mechanical syringe filling/expelling then performs powered injections while displaying syringe and programmed parameter status on a display. Readiness is indicated via an illuminated lens. Within the powerhead are the motor/encoder, gear train, drive screw & ram, ram position sensor, fill/expel control, display, tilt sensor, syringe size detection sensors, syringe holder locked sensor, and powerhead control PC board. An optional syringe heater may also be installed.
Features:
Customized Display - the user may console display to only show the control functions that are desired.
Iniection Mode - the user may select from 4 modes: angio-cardiac, angio-peripheral, auto-repeat, or CT. These modes set up the console display with the typical functions and parameter ranges for that mode. The angio-cardiac mode sets up the display with the minimum number of programmable functions while allowing the user to add functions if desired. The angio-peripheral mode sets up the display with the maximum number of programmable functions while allowing the user to remove functions if desired. The auto-repeat mode will allow the user to set up the injector to continuously repeat an injection automatically until a programmed total time has been achieved, with a programmed interval, (inject interval), between the injections. The CT mode sets up the display with the typical programmable functions for CT procedures and limits the flow rate and pressure limit to ranges that are typical for CT injectors.
Programmable Parameters - the user may enter injection parameters typical to either angiographic or CT injectors; flow rate, volume, rate rise, injection, inject delay, x-ray/scan delay, pressure limit, multiphasic injections, and inter-phase delay.
Real Time Display - the console displays the delivered volume and injection elapsed time in real time, the powerhead displays the volume remaining within the syringe.
Achieved Parameters - after each injection the console will display the achieved flow, volume, and pressure.
Stored Protocol - the user may program and store up to 99 injection protocols into the injector's injection library for convenience.
Multiphasic Injection - the user may program up to 4 phases to each injection
Inject Delay - the user may program the time that elapse from when the x-ray is started until the injection is started.
{2}------------------------------------------------
X-Ray Delay - the user may program the time that clapse from when the injection is started until the x-ray is starled.
Inter-Phase Delay - the user may program the delay time between the phases of a multiplimac uncellion This delay time is added to the end of the highlighted phase.
Inject Interval - the user may program the detay time between injections while in the auto tepeal mode.
Prefill Size - when the user installs the 125ml syringe holder assembly the user may use a prefilled syringe The user must then select the prefilled volume: 50ml, 100ml, or 125ml, The mpector then makes the necessary electronic conversions to accurately display the syringe volume
C' was the Operation - the console display serecas incorporate extra large primary parameter numbers, (flow & volumes. Tor long range visibility. All user input is guided with prompis and highlighted button look a like graphics User mistakes are guided with corrective actions. The four injection modes and customizing displayed functions assist in minimizing serven clutter.
Fill/Expel Control - the fill/expel control is a lever that will expel fluid if rotated towards the tip of the syrings and will fill the syringe when rolated away from the syringe tip. The degree that the knob is roughed determines the fill/expel flow rate. There is a detent in the fill direction that indicates the upunum fill race. (the typical maximum fill flow rate without generating a significant amount of an bubbles within the syringe ).
Powerhead Tilt Sensing - the angle of the powerhead is continuously monitored for salely reasons. When the powerhead is positioned with the syringe tip upward the injector may not perform a programmed injection, may fill/expel at the maximum fill/cxpcl flow rates, and the powerhead display is oriented in the normal reading direction. When the powerhead is rotated down to the injection position the meetor may perform a programmed injection, the fill/expel flow rate range is reduced, and the powerhead duplas is rotated 90 degrees to the appropriate reading orientation.
Intended Use:
The Angiomal Illumena is designed to inject a radiopaque contrast medium into the vascular system lur Angiographic or CT procedures as preseribed by qualified health care professionals.
{3}------------------------------------------------
Product Features Compared to Predicate Devices:
| Characteristic/Feature | Angiomat 6000(predicatedevice)(K860204) | CT9000(predicatedevice)(K912944) | AngiomatIllumena(new device) |
|---|---|---|---|
| Multiphase Operation | 9 phases per protocol | 4 phases per protocol | 4 phases per protocol |
| Protocol Storage | 99 phases | 12 protocols | 99 protocols |
| X-ray/Scan Delay | 0-255 sec | 0-99 sec | 0-300 sec |
| Inject Delay | 0-255 sec | none | 0-300 sec |
| Inter-phase Delay | none | 0-99 sec | 0-300 sec |
| Inject Interval | none | 0-99 sec | 0-300 sec |
| Syringe System | 260 ml, 150 ml, or 125 ml | 200 ml or 125 ml | 150 ml or 125 ml |
| Volume RemainingDisplay | Mechanical scale onpowerhead | Mechanical scale onpowerhead | LCD display onpowerhead |
| Fill Rate | 3 to 25 ml/sec | 2 to 7.2 ml/sec | 3 to 25 ml/sec |
| Flow Rate | 0.01 to 40 ml/sec for125/150 ml syringe0.01 to 59 ml/sec for260 ml syringe | 0.1 to 7.2 ml/sec for200 ml syringe0.1 to 4.9 ml/sec for125 ml syringe | 0.01 to 40 ml/sec for125/150 ml syringe |
| Pressure Limit | 100 to 1200 PSI | 25 to 300 PSI | 75 to 1200 PSI |
| Remote Start Switch | Yes | Yes | Yes |
{4}------------------------------------------------
Performance Test Data and Conclusions:
A comprehensive set of tests were performed to verify that the programmed flow rate, volume, duration, pressure limit, and injection/X-ray delay performance are to specification. These tests demonstrate performance to specification within ranges equivalent to the predicate devices with accuracy and precision superior to the predicate devices.
Tests were performed using extremes of operating parameters to assure operation to specification for all conditions of operation.
Fluid Delivery Performance:
The volume delivery accuracy is validated by executing injections with water throughout the operating range of the injector. The delivered volume is measured accurately via calibrated equipment and compared to the programmed volume and achieved volume displayed by the injector. Performance meets product specifications for the Angiomat Illumena.
The pressure limit accuracy is validated by executing injections with water throughout the operating range of the injector. For each test the water flow is restricted to develop back pressure. This back pressure is accurately measured via calibrated equipment and then compared to the programmed pressure limit value and the achieved pressure limit value displayed by the injector. Performance meets the product specification for the Angiomat Illumena.
The flow rate delivery accuracy is validated by executing four steps. The first step is to verify that the algorithm for determining and displaying the flow rate is correct. The second step is to verify via measurement equipment that the injector servo electronics is accurately keeping time. The third is the volume validation step listed above. This step verifies that the entire drive system, (software, electronics, motor, encoder, gear reduction/transmission, drive screw, and syringe), is being correctly incremented by the injector electronics. The fourth step is to execute injections with water throughout the operating range of the injector. For each injection the achieved flow rate value, as determined by the injector, is recorded and compared to the product specification for the Angiomat Illumena.
{5}------------------------------------------------
Image /page/5/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized image of an eagle or other bird with outstretched wings.
SEP 2 3 1997
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Ms. Bridget Drake Liebel-Flarsheim Company 2111 East Galbraith Road P.O. Box 156305 Cincinnati, Ohio 45215-6305
K963071 Re: Angiomat Illumena Requlatory Class: II (two) Product Code: 74 DXT Dated: July 3, 1997 Received: July 7, 1997
Dear Ms. Drake:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Druq, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions aqainst misbrandinq and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or requlations.
{6}------------------------------------------------
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4639. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97).
Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.qov/cdrh/dsmamain.html".
Sincerely yours,
Thomas J. Callahan
Thomas J. Callahan, Ph.D. Director Division of Cardiovascular, Respiratory, and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{7}------------------------------------------------
510(k) Number (if known): K963071
Device Name: __ ANGIOMAT ILLUMENA
Indications For Use:
The Angiomat Illumena is designed to inject a radiopaque contrast medium into the vascular system for Angiographic or CT procedures as prescribed be qualified health care professionals.
Ta Ru
(Division Sign-Off) (Division Sign-On)
Division of Cardiovascular, Respectory and Neurological Devices 510(k) Number
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use (Per 21 CFR 801.109)
OR
Over-The-Counter Use
(Optional Format 1-2-96)
§ 870.1650 Angiographic injector and syringe.
(a)
Identification. An angiographic injector and syringe is a device that consists of a syringe and a high-pressure injector which are used to inject contrast material into the heart, great vessels, and coronary arteries to study the heart and vessels by x-ray photography.(b)
Classification. Class II (special controls). The device, when it is a non-patient contacting balloon inflation syringe intended only to inflate/deflate balloon catheters and monitor pressure within the balloon, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 870.9.